Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IgG Subclass (IgG1-4) and IgA Autoantibody Profiles Against Muscle-Specific Kinase in a Greek Cohort.

Muscle & nerve·2026
Same author

Niemann Pick Type C Presenting as Familial Late-Onset Richardson Syndrome. A Case Series of Four Siblings.

Movement disorders clinical practice·2026
Same author

Clinical, Cognitive and Demographic Determinants of Work Participation in Multiple Sclerosis: A Multicenter Cross-Sectional Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Clinical Significance of Microembolic Signal Detection in Acute Ischemic Stroke: Insights Into Ongoing Cerebral Embolization and Occult Etiologies.

European journal of neurology·2026
Same author

Unraveling the genetic landscape of ALS in Greece: identification of known and novel causative variants in a 353-patient cohort.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2025
Same author

Progressive supranuclear palsy against everyone else: a look into the specificity of MRI markers.

Journal of the neurological sciences·2025

Related Experiment Videos

Circulating interleukin-15 in dementia disorders.

Michael Rentzos1, George P Paraskevas, Elisabeth Kapaki

  • 1Department of Neurology, Aeginition Hospital, Athens National University, School of Medicine, 72-74 Vas. Sophias Avenue, Athens 11528, Greece. mrentzos@med.uoa.gr

The Journal of Neuropsychiatry and Clinical Neurosciences
|September 11, 2007
PubMed
Summary
This summary is machine-generated.

Interleukin-15 (IL-15) serum levels are lower in Alzheimer's disease patients, suggesting it's not involved in dementia's immune reactions. This finding indicates potential immune hyporesponsiveness in Alzheimer's disease progression.

Related Experiment Videos

Area of Science:

  • Neuroscience
  • Immunology
  • Gerontology

Background:

  • Alzheimer's disease (AD) and vascular dementia (VaD) are major causes of cognitive decline.
  • Immune system dysregulation is increasingly recognized in neurodegenerative diseases.
  • Interleukin-15 (IL-15) is a cytokine involved in immune responses.

Purpose of the Study:

  • To investigate the role of serum Interleukin-15 (IL-15) as a marker of immune reactions in Alzheimer's disease (AD) and vascular dementia (VaD).
  • To compare IL-15 levels between AD patients, VaD patients, and healthy controls.
  • To assess the impact of acetylcholinesterase inhibitors (AChEI) treatment on IL-15 levels in AD.

Main Methods:

  • Serum IL-15 levels were measured using immunoassay in 20 AD patients, 15 VaD patients, and 15 healthy subjects.
  • Statistical comparisons were made between the groups.
  • The effect of AChEI treatment on IL-15 concentrations was analyzed.

Main Results:

  • Patients with Alzheimer's disease exhibited significantly lower serum IL-15 levels compared to healthy subjects and vascular dementia patients.
  • No significant difference in IL-15 levels was observed between healthy subjects and vascular dementia patients.
  • Serum IL-15 levels were not influenced by age, sex, disease duration, Mini-Mental State Examination score, or AChEI treatment.

Conclusions:

  • Interleukin-15 (IL-15) does not appear to be implicated in the pathogenetic mechanisms of Alzheimer's disease or vascular dementia.
  • The reduced IL-15 levels in Alzheimer's disease may suggest a state of immune hyporesponsiveness during disease progression.
  • Further research is needed to elucidate the complex interplay between immune factors and dementia pathogenesis.